Coya Therapeutics (Nasdaq: COYA) announced that patients have now been dosed in the ALSTARS Trial, the company’s Phase 2 study evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The update represents a major operational milestone for the program and triggers a $4.2 million milestone payment from Coya’s strategic partner, Dr. Reddy’s Laboratories.
A First Look at COYA 302 in a Controlled Phase 2 Setting
The ALSTARS Trial is a randomized, double-blind, placebo-controlled study enrolling patients across clinical sites in the United States and Canada. It is designed to assess the safety and efficacy of the investigational therapy COYA 302, a dual-mechanism approach aimed at two core drivers of ALS pathology: dysfunctional regulatory T cells and pro-inflammatory myeloid activity.
COYA 302 combines low-dose interleukin-2 with CTLA-4 Ig. Together, these components are intended to increase Treg number and function while reducing inflammation from activated monocytes and macrophages. Coya believes these actions may work additively or synergistically to slow disease progression.
Why This Milestone Matters
ALS remains a devastating neurodegenerative disease with limited treatment options. Launching patient dosing in a placebo-controlled Phase 2 trial allows Coya to evaluate COYA 302 in a rigorous clinical setting and generate data that could support future development decisions. The milestone payment from Dr. Reddy’s also strengthens Coya’s financial position as the program advances.
About COYA 302
COYA 302 is an investigational biologic combination therapy administered subcutaneously. It is intended to:
• enhance regulatory T-cell activity
• suppress inflammatory myeloid responses
• restore immune balance disrupted in ALS
The post Coya Therapeutics Kicks Off Phase 2 ALSTARS Dosing for COYA 302, Triggering $4.2M Milestone Payment appeared first on PRISM MarketView.